Heart Protein TSLP Reduces Post-Heart Attack Damage by Recruiting Protective Immune Cells
New research reveals how TSLP protein protects the heart after myocardial infarction by recruiting eosinophils and preventing cell death.
Summary
Researchers discovered that thymic stromal lymphopoietin (TSLP), a protein released by heart muscle cells after myocardial infarction, plays a crucial protective role in cardiac recovery. Using mouse models, they found that TSLP recruits beneficial immune cells called eosinophils to the heart, which help resolve inflammation and prevent excessive scarring. When TSLP was absent, mice experienced worse heart damage and more fibrosis. The protein works by blocking harmful cellular death pathways and promoting healing, suggesting TSLP-based therapies could improve outcomes for heart attack patients.
Detailed Summary
Heart attacks remain a leading cause of death worldwide, often leading to heart failure due to excessive inflammation and scarring. New research from Zhengzhou University reveals a surprising protective mechanism involving thymic stromal lymphopoietin (TSLP), a protein better known for its role in allergic reactions.
The study used mouse models of myocardial infarction created by blocking the left anterior descending coronary artery. Researchers compared normal mice with genetically modified mice lacking TSLP to understand the protein's role in heart recovery. They found that TSLP levels spike dramatically after heart attacks, primarily released by damaged heart muscle cells.
The key discovery was that TSLP recruits eosinophils—a type of white blood cell typically associated with allergies—to the injured heart tissue. These eosinophils proved beneficial rather than harmful, helping resolve acute inflammation within the first week after heart attack. When researchers depleted eosinophils or blocked TSLP, mice developed significantly worse heart damage and more extensive scarring.
Mechanistically, TSLP protects heart cells by inhibiting the JAK1-STAT5 signaling pathway, which prevents a destructive form of cell death called ferroptosis. This protection maintains cellular antioxidant systems and preserves mitochondrial function in heart muscle cells. The research also showed that TSLP treatment could rescue heart function even in mice genetically lacking the protein.
These findings challenge conventional thinking about post-heart attack inflammation, suggesting that certain immune responses are actually protective. The TSLP-eosinophil axis represents a potential new therapeutic target for improving heart attack outcomes and preventing heart failure development.
Key Findings
- TSLP protein levels increase dramatically in heart tissue and blood after myocardial infarction
- TSLP recruits protective eosinophils that help resolve post-heart attack inflammation
- TSLP deficiency leads to worse heart damage and increased fibrosis after heart attacks
- TSLP prevents ferroptosis cell death by inhibiting JAK1-STAT5 signaling pathway
- TSLP treatment can rescue heart function even in knockout mice
Methodology
Researchers used TSLP knockout mice and left anterior descending coronary artery ligation to model heart attacks. They employed multiple techniques including echocardiography, histological staining, flow cytometry, and Western blotting to assess cardiac function, immune cell recruitment, and molecular mechanisms over a 7-day post-infarction period.
Study Limitations
The study was conducted only in mice, and the 7-day observation period may not capture longer-term effects. The role of TSLP in human heart attack recovery requires validation in clinical studies. Additionally, the optimal timing and dosing of potential TSLP-based therapies remain to be determined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.